SEC Filing Summary: Second Sight Medical Products, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on March 19, 2020. The filing serves to announce the Company's financial and operating results for the three-month and full-year periods ended December 31, 2019. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not explicitly stated within the body of this 8-K document.
Material Changes
The filing text does not provide specific data points to compare current results against prior periods. It only confirms the issuance of results for the fourth quarter and full year 2019.
Guidance, Outlook, and Risks
The filing includes Regulation FD disclosure regarding the press release but does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies within the text provided. The document explicitly states that the information in Item 2.02 and Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and Full Year 2019.
- Verify the Company's liquidity status and runway given the date of the filing (March 2020) and the onset of the global pandemic.
- Confirm the status of the Company's primary product, the Argus II Retinal Prosthesis System, and any regulatory updates mentioned in the full press release.
- Check for any subsequent filings regarding capital raises or debt restructuring following this announcement.